SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025

About this update from Siga Technologies Inc.

Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer. " As we look forward to the remainder of 2025 and prepare for 2026, we are focused on building upon our long track record as a successful partner with the U.S. Government and international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues for the years to come.” Summary Financial Results ($ in millions, except per share amounts)Three MonthsEnded September 30 Nine Months Ended September 30 2025 2024 2025 2024Product sales (1)$0.9 $8.9 $85.8 $53.5Total revenues (2)$2.6 $10.0 $90.8 $57.3Operating (loss) / income(3) (4)$(10.2) $0.5 $33.2 $12.9(Loss) / income before income taxes(3)$(8.4) $1.9 $38.3 $17.5Net (loss) / income$(6.4) $1.3 $28.7 $13.5Diluted (loss) / income per share$(0.09) $0.02 $0.40 $0.19 (1)Includes supportive services related to product sales.(2)Includes research and development revenues.(3)Operating (loss) / income excludes, and income (loss) before income taxes includes, other income. Both line items exclude the impact of income taxes.(4)Differences in operating income margin between periods reflects different product mixes in those periods. Year-to-Date Key Business and Operational Activity: For the first nine months of the year, the Company generated $53 million of oral TPOXX revenues and $26 million of IV TPOXX revenues in connection with deliveries to the U.S. Strategic National Stockpile, or SNS. Additionally, the Company delivered $6 million of oral TPOXX to an international customer, representing a sale to this country in five out of the last six years.In June 2025, the Company’s Biomedical Advanced Research and Development Authority, or BARDA, 19C contract (with the U.S. Government) was modified to add $13 million of funding to the Company’s TPOXX pediatric development program. In combination with the $14 million of funding added in April 2025 to support manufacturing activities, $27 millio...

View stock analysis, news, and events for Siga Technologies Inc.